Cargando…

Continuous Subcutaneous Levodopa Delivery for Parkinson’s Disease: A Randomized Study

BACKGROUND: ND0612 is a continuous, subcutaneous levodopa/carbidopa delivery system in development for patients with Parkinson’s disease (PD) experiencing motor fluctuations OBJECTIVE: Evaluate the efficacy and safety of two ND0612 dosing regimens in patients with PD. METHODS: This was a 28-day open...

Descripción completa

Detalles Bibliográficos
Autores principales:	Olanow, C. Warren, Espay, Alberto J., Stocchi, Fabrizio, Ellenbogen, Aaron L., Leinonen, Mika, Adar, Liat, Case, Ryan J., Orenbach, Shir Fuchs, Yardeni, Tami, Oren, Sheila, Poewe, Werner
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2021
Materias:	Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990424/ https://www.ncbi.nlm.nih.gov/pubmed/33164945 http://dx.doi.org/10.3233/JPD-202285

Ejemplares similares

Subcutaneous Levodopa Infusion for Parkinson's Disease: 1‐Year Data from the Open‐Label BeyoND Study
por: Poewe, Werner, et al.
Publicado: (2021)

The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development program
por: LeWitt, Peter A., et al.
Publicado: (2022)

Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson’s disease patients with wearing-off
por: Kuoppamäki, Mikko, et al.
Publicado: (2015)

Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease
por: Ferreira, Joaquim J., et al.
Publicado: (2022)

Opicapone Pharmacokinetics and Effects on Catechol-O-Methyltransferase Activity and Levodopa Pharmacokinetics in Patients With Parkinson Disease Receiving Carbidopa/Levodopa
por: LeWitt, Peter, et al.
Publicado: (2023)

Opicapone as an Add-on to Levodopa in Patients with Parkinson’s Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial
por: Ferreira, Joaquim J., et al.
Publicado: (2022)

IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease: The RISE-PD Randomized Clinical Trial
por: Hauser, Robert A., et al.
Publicado: (2023)

Levodopa in the treatment of Parkinson’s disease: an old drug still going strong
por: Poewe, Werner, et al.
Publicado: (2010)

Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson's Disease Receiving ≥2000 mg Daily Dose of Levodopa
por: Zadikoff, Cindy, et al.
Publicado: (2020)

Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety
por: Poewe, Werner, et al.
Publicado: (2019)

Levodopa–carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry
por: Poewe, Werner, et al.
Publicado: (2019)

Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study
por: McGarry, Andrew, et al.
Publicado: (2020)

Predictors of Response for “Off” Time Improvement With Levodopa-Carbidopa Intestinal Gel Treatment: An Analysis of the GLORIA Registry
por: Poewe, Werner, et al.
Publicado: (2020)

Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation
por: LeWitt, Peter, et al.
Publicado: (2023)

The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II
por: Rocha, José-Francisco, et al.
Publicado: (2021)

The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II
por: Rocha, José-Francisco, et al.
Publicado: (2022)

Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity
por: Werner, Milton H., et al.
Publicado: (2021)

Diffuse Facial Hyperpigmentation as a Presenting Sign of Lupus Erythematosus: Three Cases and Review of the Literature
por: Azrielant, Shir, et al.
Publicado: (2021)

Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease
por: Hauser, Robert A, et al.
Publicado: (2018)

Continuous levodopa for advanced Parkinson’s disease
por: Lundqvist, Christofer
Publicado: (2007)

Foslevodopa/Foscarbidopa Is Well Tolerated and Maintains Stable Levodopa and Carbidopa Exposure Following Subcutaneous Infusion
por: Rosebraugh, Matthew, et al.
Publicado: (2021)

Continuous 24-h Levodopa-Carbidopa Intestinal Gel Infusion After a Levodopa Holiday Suppressed Refractory Dyskinesia Despite Increasing Levodopa Dose
por: Nishikawa, Noriko, et al.
Publicado: (2022)

A Randomized Thorough QT Study of Apomorphine Sublingual Film in Patients With Parkinson's Disease
por: Stocchi, Fabrizio, et al.
Publicado: (2022)

Pharmacokinetics of Intravenously (DIZ101), Subcutaneously (DIZ102), and Intestinally (LCIG) Infused Levodopa in Advanced Parkinson Disease
por: Bergquist, Filip, et al.
Publicado: (2022)

L-Dopa Pharmacokinetic Profile with Effervescent Melevodopa/Carbidopa versus Standard-Release Levodopa/Carbidopa Tablets in Parkinson's Disease: A Randomised Study
por: Stocchi, Fabrizio, et al.
Publicado: (2015)

Aromatic L‐Amino Acid Decarboxylase Gene Therapy Enhances Levodopa Response in Parkinson's Disease
por: Nutt, John G., et al.
Publicado: (2020)

Gender Differences in Levodopa Pharmacokinetics in Levodopa-Naïve Patients With Parkinson’s Disease
por: Conti, Valeria, et al.
Publicado: (2022)

Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy
por: Espay, Alberto J., et al.
Publicado: (2017)

Burden of non‐motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa‐carbidopa intestinal gel
por: Ray Chaudhuri, K., et al.
Publicado: (2018)

Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations
por: Borgohain, Rupam, et al.
Publicado: (2014)

Levodopa-Induced Pseudopheochromocytoma
por: Cardoso, Joana, et al.
Publicado: (2023)

P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson’s Disease
por: Hauser, Robert A., et al.
Publicado: (2022)

Integrated safety of levodopa‐carbidopa intestinal gel from prospective clinical trials
por: Lang, Anthony E., et al.
Publicado: (2015)

Levodopa-induced respiratory dysfunction confirmed by levodopa challenge test: A case report
por: Ko, Pan-Woo, et al.
Publicado: (2018)

Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa
por: Othman, Ahmed A., et al.
Publicado: (2017)

Comparison of the pharmacokinetics of an oral extended‐release capsule formulation of carbidopa‐levodopa (IPX066) with immediate‐release carbidopa‐levodopa (Sinemet(®)), sustained‐release carbidopa‐levodopa (Sinemet(®) CR), and carbidopa‐levodopa‐entacapone (Stalevo(®))
por: Hsu, Ann, et al.
Publicado: (2015)

Mathematical Insights into the Effects of Levodopa
por: Reed, Michael C., et al.
Publicado: (2012)

Thrombocytopenia Associated with Levodopa Treatment
por: Lee, Ku-Eun, et al.
Publicado: (2013)

Orthostatic stability with intravenous levodopa
por: Siddiqi, Shan H., et al.
Publicado: (2015)

The Human Experience with Intravenous Levodopa
por: Siddiqi, Shan H., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_7hgo5bm54r36qj6tfmihlp5ppr